Conexeu Sciences (CNXU) Corporate presentation summary

Market opportunity and unmet needs

• Addressable market exceeds $20B across medical aesthetics, dental, wound care, veterinary, and 3D bioprinting sectors, with medical aesthetics alone valued at $11B and dental at $4.2B.

• Current ECM and dermal filler technologies are outdated, failing to address new needs such as GLP-1-induced tissue loss and complex wound geometries.

• GLP-1 drugs are driving a new $2B+ market for tissue restoration, with 1 in 8 U.S. adults using these medications and 62% concerned about loose skin.

Technology and product overview

• CXU is a patented, biomimetic, thermosensitive ECM scaffold that transitions from liquid to gel at body temperature, enabling precise placement and rapid in situ gelation.

• Designed to support cellular infiltration, vascularization, and native tissue remodeling, mimicking native ECM for improved integration and outcomes.

• Shelf-stable lyophilized powder format allows for ambient storage, easy reconstitution, and compatibility with standard clinical workflows.

Clinical and regulatory strategy

• Predicate-based 510(k) regulatory pathway aims to reduce cost and time to market, with initial FDA submission targeted for Q1 2027 and staged expansion into dental, veterinary, and aesthetics markets.

• CXU is currently investigational, with preclinical data supporting its safety and efficacy; not yet FDA-cleared for commercial use.

• Regulatory strategy includes a transition from bovine to human collagen for aesthetics, leveraging a single platform for multiple indications.